Floatz logo

Xaliplatin

Nodal Marginal Zone B-Cell Lymphoma

Izidore Lossos, MDSmall moleculePhase 2Active
B
61/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
81/ 100

Competitive context

34 Active assets in the Nodal Marginal Zone B-Cell Lymphoma cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
SWOG Cancer Research Network
Phase 2BB
Etoposide
University of California, Davis
Phase 2BB
Fludarabine
UNC Lineberger Comprehensive Cancer Center
Phase 2BB
Dexasone
Izidore Lossos, MD
Phase 2BB
Cediranib
National Cancer Institute (NCI)
Phase 2BB

View all 50 →

Same molecule, other indications

Xaliplatin is also rated in:

exocrine pancreatic carcinomaActive
BBB
Indicative · Phase 2/3
78 / 100
View asset →
colon adenocarcinomaActive
BBB
Indicative · Phase 3
77 / 100
View asset →
rectal cancerActive
BBB
Indicative · Phase 3
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →